Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05554302 · ClinicalTrials.gov registry record · Phase 2
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
A Phase 2 study of Brain Metastases and Brain Cancer, sponsored by Baptist Health South Florida.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05554302 is a Phase 2 study of Brain Metastases and Brain Cancer that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 20 participants, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05554302, a Phase 2 study of Brain Metastases and Brain Cancer, is actively recruiting participants, sponsored by Baptist Health South Florida.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.
Conditions Studied
Interventions
- DRUG 18F-Fluciclovine
Study Locations (1)
Florida
- Miami Cancer Institute at Baptist Health South Florida - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-01-10 |
| Est. Completion | 2030-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05554302
The ClinicalTrials.gov registry entry for NCT05554302 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (91% lower). The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which 18F-Fluciclovine is the first listed.
NCT05554302 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05554302 about?
NCT05554302 is a clinical study titled "Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis". This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific ...
What is the current status of trial NCT05554302?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-01-10. Estimated completion is 2030-01.
What conditions does trial NCT05554302 study?
This clinical trial studies the following conditions: Brain Metastases, Brain Cancer.
What interventions are being tested in trial NCT05554302?
The interventions under investigation include: 18F-Fluciclovine (DRUG).
Who is sponsoring clinical trial NCT05554302?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05554302 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.